Revitope Oncology will be open to CRO and CMO pitches in a couple of months for a Phase I trial after it selects its development candidate, said Chief Scientific Officer Werner Meier. The company will most likely nominate its REV-100 molecule for colorectal cancer, he added.
The Cambridge, Massachusetts-based company has decided to keep its research in-house but is looking to outsource all development operations, said Meier. Revitope is speaking with CROs but is still in the early stages of discussions, he added. It will seek CROs with the ability to help drive its product from selection through use in clinics, and is eager to build long-lasting relationships, said Meier. CRO location is unimportant. Revitope will also look for a CMO with the ability to manage everything from cell line development through drug production, he explained.
In December 2020, Revitope announced a $10m investment from Junshi Biosciences in exchange for 9.9% of its shares, and the two companies will collaborate to deliver precision cancer therapies. Junshi shares the product rights for Revitope’s REV-200 and REV-300 molecules for solid cancers. Revitope’s technology is called the T-cell engager antibody circuit (TEAC) and it divides antibodies into inactive halves, which then only activate when they encounter a cell expressing both antigens.
Sean Rai-Roche is a Reporter for Clinical Trials Arena parent company GlobalData’s investigative journalism team. A version of this article originally appeared on the Insights module of GlobalData’s Pharmaceutical Intelligence Center. To access more articles like this, visit GlobalData.